{
    "RADCURE-3309": {
        "question": "Age: 22.3, Sex: Male, ECOG PS: ECOG 1, Smoking PY: 66, Smoking Status: Current, Ds Site: Larynx, Subsite: Supraglottis, T: T2, N: N2c, M : M0, Stage: IVA, Path: Squamous Cell Carcinoma, HPV: none, Tx Modality: RT alone, Chemo? : none, Dose: 60.0, Fx: 25, Local: Yes, Regional: none, Distant: none, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for head and neck squamous cell carcinoma, especially HPV-negative cases involving the larynx. - Hierarchy: Radiation Oncologist",
        "initial_assessment-radiation oncologist": "Step-by-step analysis as a radiation oncologist:\n\n1. The provided bounding box coordinates are [[259, 156, 85, 259, 188, 108], [259, 156, 85, 259, 188, 108]]. Both boxes are identical, indicating a single region of interest (ROI) within the CT scan.\n\n2. The coordinates are normalized relative to the original image size, but without the original image dimensions, exact anatomical localization is limited. However, the z, y, x ranges suggest a relatively small, focused volume.\n\n3. The CT scan is of the head and neck region. The ROI likely corresponds to a specific anatomical structure or lesion within this area.\n\n4. From a radiation oncology perspective, the ROI could represent a tumor volume, nodal disease, or an organ at risk (OAR).\n\n5. No visible abnormalities or anatomical structures can be definitively described without viewing the actual CT images or additional clinical context.\n\n6. Without further clinical data (tumor site, stage, pathology, HPV status), it is not possible to estimate survival probability or treatment outcomes.\n\nFinal answer:\nAnswer:Alive",
        "initial_assessment_review_assessment-radiation oncologist": "Answer:Dead",
        "Round 1-role-comment": "radiation oncologist:dead",
        "Round 1-num_agents": 1,
        "Round 2-Turn 1-discuss-participate_review_assessment-radiation oncologist": "no  \nAnswer:Dead",
        "Round 2-Turn 1-ask_gap_review_assessment-radiation oncologist": "---\nAnswer: yes  \nReason: multidisciplinary input required  \n---",
        "Round 2-Turn 1-gap_identified-assistant": "Unique, useful, and specific expert recommendations extracted:\n\n- Multidisciplinary input required (implying consultation with medical oncology and surgical oncology for comprehensive management of stage IVA supraglottic laryngeal squamous cell carcinoma).",
        "Round 2-Turn 1-gap_recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in head and neck cancers. - Hierarchy: Medical Oncologist == Radiation Oncologist\n2. Surgical Oncologist (Recurrence/Secondary Cancers) - Your expertise is strictly limited to evaluating surgical options for recurrent or secondary malignancies in head and neck cancers. - Hierarchy: Surgical Oncologist == Radiation Oncologist",
        "Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "Step-by-step analysis as a medical oncologist:\n\n1. Patient is a young male (22.3 years) with a significant smoking history (66 pack-years) and currently smoking, which negatively impacts prognosis.\n2. The primary tumor site is the larynx, specifically the supraglottis, which is a common site for squamous cell carcinoma.\n3. Tumor staging is T2N2cM0, indicating a moderately advanced local tumor with bilateral lymph node involvement but no distant metastasis. This corresponds to Stage IVA disease.\n4. Pathology confirms squamous cell carcinoma, which is the most common histology in head and neck cancers.\n5. HPV status is negative, which generally correlates with a worse prognosis compared to HPV-positive tumors.\n6. Treatment was radiation therapy alone (60 Gy in 25 fractions) without chemotherapy, which may be suboptimal for N2c disease where concurrent chemoradiation is often recommended.\n7. No evidence of local, regional, or distant recurrence or second cancers at the time of imaging.\n8. ECOG performance status is 1, indicating the patient is symptomatic but ambulatory, which is favorable for treatment tolerance.\n9. The provided CT scan with bounding boxes likely highlights the tumor and involved lymph nodes, but no direct image abnormalities are described here.\n10. Given the advanced nodal stage, negative HPV status, and treatment without chemotherapy, the risk of recurrence and mortality is higher than in HPV-positive or chemoradiated patients.\n\nConsidering these factors, the patient's survival probability is guarded but not immediately poor. Close follow-up and possible additional therapy might be needed.\n\nAnswer: Alive",
        "Round 2-Turn 1-gap_recruited_assessment_review_assessment-medical oncologist": "Answer:Dead",
        "Round 2-Turn 1-gap_recruited_assessment-surgical oncologist (recurrence/secondary cancers)": "Step-by-step analysis as a surgical oncologist (recurrence/secondary cancers):\n\n1. Patient demographics and clinical data:\n   - Age: 22.3 years (young patient)\n   - Male, ECOG 1 (good performance status)\n   - Heavy smoker (66 pack-years), current smoker\n   - Primary site: Larynx, specifically supraglottis\n   - Tumor staging: T2 (tumor limited to supraglottis but >2 cm), N2c (bilateral lymph node involvement), M0 (no distant metastasis)\n   - Stage IVA (locally advanced disease)\n   - Pathology: Squamous cell carcinoma, HPV negative (worse prognosis compared to HPV positive)\n   - Treatment: Radiation therapy alone, no chemotherapy, dose 60 Gy in 25 fractions\n   - Response: Local control achieved, no regional or distant disease, no second cancer\n   - Contrast enhanced CT provided with masked ROI at coordinates [259,156,85,259,188,108] (same box repeated twice)\n\n2. Imaging interpretation:\n   - The bounding box coordinates correspond to a small volume in the head and neck CT scan.\n   - Given the location (larynx, supraglottis), the ROI likely includes the primary tumor site or involved lymph nodes.\n   - No mention of residual or recurrent disease in the ROI.\n   - No evidence of distant metastasis or second primary tumors.\n   - The absence of regional or distant disease post-treatment suggests good local control.\n\n3. Prognostic considerations:\n   - Young age and good performance status are favorable.\n   - Heavy smoking and HPV negativity are adverse factors.\n   - N2c nodal status indicates bilateral lymph node involvement, which increases risk of recurrence.\n   - Treatment with RT alone without chemotherapy in stage IVA disease may be suboptimal, potentially increasing risk of recurrence.\n   - However, current imaging shows no active disease.\n\n4. Surgical oncologist perspective on recurrence risk and survival:\n   - The risk of recurrence remains due to nodal involvement and lack of chemotherapy.\n   - Close surveillance is warranted.\n   - If recurrence occurs, surgical salvage may be considered depending on location and extent.\n   - Overall, the patient has a reasonable chance of survival with current local control but remains at risk for recurrence.\n\nFinal answer:\n\nAnswer:Alive",
        "Round 2-Turn 1-gap_recruited_assessment_review_assessment-surgical oncologist (recurrence/secondary cancers)": "Answer:Alive",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate_review_assessment-medical oncologist": "Answer:Dead",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate_review_assessment-surgical oncologist (recurrence/secondary cancers)": "Answer:Dead",
        "Round 2-role-comment": "radiation oncologist:dead|medical oncologist:dead|surgical oncologist (recurrence/secondary cancers):alive",
        "Round 2-num_agents": 3,
        "num_cooperations-panel": 0,
        "decision-Moderator": "(radiation oncologist): Answer: Alive\n(medical oncologist): Answer: Alive\n(surgical oncologist (recurrence/secondary cancers)): Answer: Alive\n\n('Answer: Alive',)"
    }
}